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Introduction
Endometriosis (EM) is a common and refractory gynecological disease. Although it is an estrogen-dependent benign disease, its biological behaviors are similar to those of malignant tumors. It is characterized by infiltrated distribution, diverse morphology, local invasion, distant metastasis, and recurrence. There are different theories to explain the pathogenesis of endometriosis, among which the classical theory of "retrograde menstruation" is widely accepted. However, this theory does not explain the common physiological phenomenon of blood reflux in women of reproductive age, which has an incidence of approximately 90%, whereas the incidence of endometriosis is only 10%-15% [1] . This suggests that additional factors contribute to the pathogenesis of endometriosis. Molecular defects that predispose endometrial cells to endometriosis may act synergistically with micro-environmental factors in the pelvis to promote the establishment of endometriotic lesions. Burney [2] and Li [3] showed that the gene expression profile of the eutopic endometrium of endometriosis is significantly different from that of the normal endometrium. Altered expression of genes related to cell adhesion [4] and invasion [5] result in the functional changes of eutopic cells and provide the basic conditions for ectopic implantation. Abnormal autoimmune function and increased estrogen metabolism in ectopic endometrium also play important roles in the occurrence of endometriosis.
The breast cancer anti-estrogen resistance 3 (BCAR3) gene, also known as AND-34 or NSP2, belongs to the novel Src homology 2 (SH2) -containing protein (NSP) family [6] . The BCAR3 protein is responsible for the resistance of estrogen-dependent breast cancer cells to anti-estrogen drugs in vitro, which is an important cause of the failure of endocrine therapy in estrogen-receptor-positive breast cancer patients. Anti-estrogen in ectopic endometrium is a protective factor against the occurrence of endometriosis, and inhibition of the local anti-estrogenic effect promotes the formation of ectopic lesions [7] . Therefore, the potential role of
BCAR3 as a candidate gene promoting the malignant behaviors of cells is worth
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exploring. Abnormal overexpression of BCAR3 can also induce cytoskeleton rearrangement and promote cell adhesion, migration, and invasion [8] . BCAR3 is highly expressed in breast cancer, ovarian cancer [9] , and most endometrial cancer cells, although the role of BCAR3 in endometriosis has not been reported to date.
In recent years, microRNAs (miRNAs), which are small RNA molecules that regulate gene expression, have attracted attention for their role in the pathogenesis of many diseases. The miRNAs regulate target gene expression negatively through incomplete complementary pairing with the 3′-untranslated region (3′-UTR) of target genes [10] . A previous study from our group showed that low expression of miR-126-3p in eutopic endometrial stromal cells (ESCs) of patients with endometriosis leads to increased invasiveness [11] . MiR-126-5p and miR-126-3p are derived from the same precursor, pre-mir-126 [12] . They are expressed at the same level in various tissues and cells, have similar variation trends, and play similar functions [13] . The expression of miR-126-5p is low in many cancers, and it can be used as an anti-oncogene to inhibit the migration and invasion of cancer cells [14] . The results of DIANA-microT and Targetscan algorithm showed that BCAR3 gene was one of the downstream targets of miR-126-5p [15, 16] . Whether miR-126-5p can regulate the invasiveness of ESCs by targeting BCAR3 remains to be verified.
Epithelial-mesenchymal transition (EMT) is a basic biological process for the maintenance of living tissues and also a key step in the invasion and metastasis of epithelial-derived cancer cells [17] . EMT is characterized by decreased expression of E-cadherin, an epithelial marker, and increased expression of mesenchymal markers such as fibronectin and vimentin [18] . Compared with eutopic endometrium, the proportion of epithelial to stromal cells is inverted in ectopic endometrium, and endometrial epithelial cells (EECs) are often missing in ectopic lesions [19] . Changes of EMT marker proteins have been detected in ectopic epithelial cells showing enhanced migration and invasion [20] . However, the mechanism underlying the function of EMT in endometriosis remains unclear. BCAR3 was shown to induce EMT in tumor cells [21] , and estrogen promotes EMT in endometriosis. Therefore, whether BCAR3 cooperates with estrogen to promote EMT in endometriosis is worth exploring.
The present study investigated the effect of BCAR3 on the invasiveness of endometriosis stromal cells and its possible regulatory mechanism to provide a new theoretical basis for the pathogenesis of endometriosis. 
Immunohistochemistry
The formaldehyde-fixed paraffin-embedded tissue was sliced into 4 µm sections.
After blocking with 10% normal goat serum, the sections were incubated with Lakes, NJ, USA).
Statistical analysis
Statistical analysis was performed using SPSS 21.0 (IBM, Chicago, IL, USA).
Comparison among multiple groups were performed by one-way analysis of variance followed by the Bonferroni (equal variances) or Dunnett's (unequal variances) post-hoc tests. Differences between two groups were tested by Student's t-test. The correlation was analyzed using the Pearson's correlation test. Values are expressed as the mean ± SEM, and differences were considered statistically significant when P < 0.05.
Results
Upregulation of BCAR3 in eutopic and ectopic endometrium
The expression levels of BCAR3 in Ec, Eu, and NE were examined by RT-qPCR, western blotting, and immunohistochemistry. As shown in Fig. 1A , we found that BCAR3 staining was seen in cellular nuclei and cytoplasm in both the stromal and epithelial cells of the normal, eutopic and ectopic endometrium. BCAR3 expression was significantly higher in endometriotic epithelial cells (EcECs) than in EECs and NEECs, which had similar expression levels (P < 0.05). In stromal cells, BCAR3 M A N U S C R I P T
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protein expression was highest in EcSCs, lower in ESCs, and lowest in NESCs (P < 0.01). Western blotting results showed that BCAR3 expression was higher in Ec and in Eu than in NE (P < 0.01), and it was higher in patients with stage III/IV endometriosis than in those with stage I/II (P < 0.05, Fig. 1B and D) . BCAR3 mRNA level was also higher in Ec and Eu than in NE (P < 0.05, Fig. 1C ). However, BCAR3
mRNA expression did not differ between patients with early-and advanced-stage endometriosis (Fig. 1D ).
Correlation analysis of BCAR3 and miR-126-5p
The expression of miR-126-5p in Ec, Eu, and NE is shown in Fig. 2A . There were significant differences in the expression level of miR-126-5p between Ec (0.36 ± 0.04) and Eu (0.40 ± 0.04), as well as between Eu and NE (1.09 ± 0.09). Correlation analysis showed that miR-126-5p was negatively correlated with BCAR3 mRNA (r=-0.417, P < 0.01) and BCAR3 protein expression (r=-0.669, P < 0.01; Fig. 2B and C).
The expression of EMT markers in eutopic and ectopic endometrium
Immunohistochemical results showed that vimentin, a mesenchymal marker, was expressed at similar levels in endometriotic stromal cells (EcSCs), ESCs, and NESCs (P > 0.05, Fig. 3A) , and its expression was higher in EcECs than in EECs and normal endometrial epithelial cells (NEECs) (P < 0.01, Fig. 3A) , whereas E-cadherin, an epithelial marker, was only expressed in epithelial cells and not in stromal cells. Its expression was significantly lower in EcECs than in EECs (P < 0.01, Fig. 3B ).
E-cadherin expression levels were similar in EECs and NEECs (P > 0.05, Fig. 3B ).
3.4 Downregulation of miR-126-5p promotes migration and invasion of ESCs.
To evaluate the possible role of miR-126-5p in ESCs, we measured cell migration and invasion using the Transwell assay after transfecting miR-126-5p antagomir into
NESCs and miR-126-5p agomir into ESCs. The transfection efficiency was verified by RT-qPCR (Fig. 4A) . Compared with negative controls, overexpression of miR-126-5p markedly repressed the migration and invasion of ESCs, whereas downregulation of miR-126-5p promoted migration and invasion of NESCs ( Fig. 4B and C).
3.5 BCAR3 overexpression promotes the proliferation, migration, and invasion of ESCs.
BCAR3 expression was significantly higher in ESCs than in NESCs (BCAR3 mRNA, P < 0.01, Fig. 5A ; BCAR3 protein, P < 0.01, Fig. 5B ). To determine whether M A N U S C R I P T
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BCAR3 plays a role in the migration and invasion of stromal cells, ESCs were infected with siBCAR3-lentivirus and NESCs were infected with BCAR3-lentivirus (P < 0.01, Fig. 5C ). As shown in Fig. 5D and E, compared with the control group, cell migration and invasion were markedly suppressed in BCAR3 silenced ESCs and significantly promoted in BCAR3-overexpressing NESCs.
3.6 BCAR3 is the direct target of miR-126-5p.
Using DIANA-microT and TargetScan algorithms [15, 16] , we identified BCAR3 as a predicted target gene of miR-126-5p (Fig. 6A) . Correlation analysis showed that miR-126-5p expression was negatively correlated with BCAR3 mRNA and protein expression. We then constructed WT-BCAR3 3′-UTR and the corresponding Mut-BCAR3 3′-UTR luciferase reporters (Fig. 6B ) and performed luciferase activity assays in HEK293T cells. The results showed that miR-126-5p overexpression reduced the luciferase activity of the WT-BCAR3 3′-UTR but not that of the Mut-BCAR3 3′-UTR construct (P < 0.01, Fig. 6C ). To determine whether BCAR3
was regulated by miR-126-5p, NESCs were transfected with miR-126-5p antagomir and ESCs were transfected with miR-126-5p agomir, and the protein expression of BCAR3 was measured. As shown in Figure 6C , silencing of miR-126-5p increased BCAR3 protein expression in NESCs, whereas overexpression of miR-126-5p decreased BCAR3 protein expression in ESCs.
To further explore whether BCAR3 mediated the invasion-suppressive effects of miR-126-5p, BCAR3 was silenced in miR-126-5p stably silenced NESCs (Fig. 6D) .
The results showed that the effect of miR-126-5p downregulation on promoting NESC migration and invasion was partially reversed by BCAR3 silencing (Fig. 6E and F). Upregulation of BCAR3 in miR-126-5p stably overexpressed ESCs (Fig. 6G) modestly reversed the repressive effect of miR-126-5p on ESC migration and invasion ( Fig. 6H and I ).
Effect of BCAR3 and estrogen on EMT in EECs
As shown in Fig. 7A , EECs infected with BCAR3-lentivirus showed significantly increased BCAR3 expression (P < 0.05). Compared with the controls, BCAR3
overexpressing cells showed increased fibronectin expression (P < 0.05, Fig. 7B ) and mesenchymal-like morphology, characterized by disaggregation of spindle-like cells (Fig. 7C) . However, no significant changes in the expression of E-cadherin and vimentin were observed (P > 0.05, Fig. 7B ).
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Compared with control cells, estrogen-treated EECs showed decreased expression of E-cadherin (P < 0.05) and increased expression of vimentin (P < 0.01), and these changes were abolished by estrogen receptor antagonist ICI182780 (Fig.   7D ). In addition, estrogen treatment changed EEC morphology from tightly-arranged round cells to scattered spindle-like cells (Fig. 7F ).
EECs treated with estrogen at 24 h after BCAR3-lentivirus infection showed a higher expression of fibronectin (Fig. 7E) and an earlier alteration of cell morphology (Fig. 7F) than those in the estrogen-only intervention group and recombinant BCAR3 group. The expression levels of E-cadherin and vimentin were similar between the estrogen intervention plus recombinant BCAR3 group and the estrogen-only intervention group (P < 0.05, Fig. 7E ).
Discussion
The results of the present study showed that BCAR3 was highly expressed in ectopic and eutopic endometrium of endometriosis, and the expression level of BCAR3 had no effect on EMT and no synergistic effect with estrogen on promoting EMT.
Endometriosis is an estrogen-dependent multifactorial disease. In recent years, studies on the pathogenesis of endometriosis focused on "abnormal endometrium gene expression," "immune dysfunction" and "stem cell theory." The enhanced M A N U S C R I P T
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bioavailability of estrogen in ectopic lesions is an important factor in endometriosis [22, 23] . Delvoux, B. et al. [22] and Smuc, T. et al. [23] reported that patients with endometriosis have abnormal expression of aromatase and 17 beta-HSD genes, indicating that the synthesis and secretion of estrogen are increased in ectopic lesions .
Inhibition of estrogen or anti-estrogen in ectopic endometrium contributes to their failure to form lesions, which is a protective factor against the occurrence of endometriosis. Endometrium apoptosis is caused by immune rejection and the anti-estrogenic effect after blood reflux. Therefore, inhibition of the anti-estrogenic effect of ectopic endometrium may lead to endometriosis, which is rarely reported.
BCAR3 can induce antiestrogen drug resistance in estrogen-dependent breast cancer cells, leading to failure of endocrine therapy in estrogen-receptor-positive breast cancer patients [24] . The role of BCAR3 in breast cancer, ovarian cancer, endometrial cancer, and other tumors has been reported. Studies show that [25] , compared with control cells, the number of stress fibers transfected with BCAR3 is reduced in breast cancer cells, the arrangement is disordered, and the actin skeleton is reconstructed.
Wilson et al. reported that BCAR3 alters actin cytoskeletal and adhesion remodeling, and increases the number of plate pseudopods, suggesting that the upregulation of BCAR3 enhances the movement and invasive abilities of cells [26] . In the present study, we showed for the first time that the expression of BCAR3 was abnormally upregulated in eutopic endometrium and ectopic endometrium of endometriosis. In addition, BCAR3 expression was positively correlated with the severity of the disease, and BCAR3 promoted the migration and invasion of eutopic ESCs, suggesting that BCAR3 might be one of the targets of eutopic endometrium of endometriosis.
Whether BCAR3 affects the anti-estrogen inhibition in ectopic endometrium needs to be determined. BCAR3 may indirectly promote the effects of estrogen on ectopic endometrium, and the underlying mechanism needs to be explored.
EMT plays an important role in the occurrence of endometriosis [27] . Estrogen can induce EMT in endometriosis and is involved in the development of endometriosis [28, 29] . In adenomyosis, circulating estrogen levels are positively correlated with EMT [30] .
Here, we demonstrated that the eutopic endometrium of endometriosis has higher EMT abilities. In vitro experiments showed that estrogen decreased the expression of E-cadherin and increased the expression of vimentin and fibronectin in eutopic EECs, M A N U S C R I P T
suggesting that estrogen may promote EMT in ectopic endometrium. Cai and Near recently reported that overexpression of BCAR3 alters the growth pattern of mammary epithelial cells from a polygonal cell mass to multi protuberant independent cells, and induces EMT in cells [21, 31] . Based on these findings, we investigated whether the occurrence and development of endometriosis are related to the potential effect of BCAR3 on inhibiting the anti-estrogen effect of ectopic endometrium and acting synergistically with estrogen to promote EMT. However, our results showed that transfection of BCAR3 into eutopic endometrial cells did not upregulate the expression of E-cadherin and vimentin in epithelial cells. The expression of E-cadherin and vimentin in epithelial cells increased in response to treatment with estrogen, whereas the expression levels were the same in the estrogen and BCAR3
plus estrogen groups. This suggested that BCAR3 had no effect on EMT in endometriosis, and the mechanism underlying the role of the BCAR3 gene in endometriosis may not be related to EMT.
In previous work from our group, we showed that the expression of miR-126-3p
was low in the eutopic endometrium of endometriosis [11] . miR-126-5p and miR-126-3p are derived from the same precursor and have similar functions. The expression levels of miR-126-5p and miR-126-3p were similar in melanoma [32] , lung cancer [33] , breast cancer [34] , and their changing trends were the same, playing similar roles [35] . In vitro experiments showed that the expression of miR-126-5p was also low in endometriosis, and upregulation of miR-126-5p expression in eutopic ESCs could inhibit cell migration and invasion. Conversely, downregulation of miR-126-5p in NESCs could enhance cell migration and invasion. This conclusion is consistent with Musiyenko's report indicating that low expression of miR-126-5p promotes the invasion of prostate cancer cells [36] . The results of luciferase experiments indicated that miR-126-5p could directly bind to the 3′-UTR of BCAR3. Further validation experiments showed that the downregulation of miR-126-5p negatively regulated BCAR3 gene expression and promoted the migration and invasion of endometriotic stromal cells. miR-126-5p was identified as an upstream regulator of BCAR3, suggesting its potential as a molecular marker of endometriosis. This molecular pathway needs to be investigated in-depth. However, this study may have been underpowered given only Han population included since recent evidences showed the divergence in miRNAs expression among different ethnic groups [37, 38] .
In conclusion, the downregulation or loss of miR-126-5p expression in eutopic 
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